IFLI - Institute for Follicular Lymphoma Innovation

Our mission is to empower our partners in creating groundbreaking treatments that deliver life-changing results for patients with #follicular #lymphoma. We are inspired by Pepromene Bio's unwavering dedication to innovation and the promising potential of PMB-CT01 in treating #NHL. IFLI - Institute for Follicular Lymphoma Innovation is committed to driving the company's growth and success. 🌟 The Leukemia & Lymphoma Society, City of Hope, Pepromene Bio larry kwak, Hazel Cheng, John Fry, Beth Fordham-Meier, Shwetha Lakshmipathi, Ph.D., Agatha Lee, PhD, Michel Azoulay, MD, MBA, Dave McCullagh, Tracy Dooley MD https://lnkd.in/e4mqxfUD

Innate Pharma together with the IFLI - Institute for Follicular Lymphoma Innovation today announced that they have entered into an agreement to clinically study the potential of IPH6501,  a first-in-class tetra-specific NK cell engager armed with a variant of IL-2, targeting CD20  ANKET® in #follicular #lymphoma (FL). 👏 https://lnkd.in/eUPv-Ejk

Fantastic work! Bravo

Delighted to ink IFLI - Institute for Follicular Lymphoma Innovation’s investment to expand Innate Pharma’s Phase 1/2 IPH6501 to #follicularlymphoma.

Innate Pharma together with the IFLI - Institute for Follicular Lymphoma Innovation today announced that they have entered into an agreement to clinically study the potential of IPH6501,  a first-in-class tetra-specific NK cell engager armed with a variant of IL-2, targeting CD20  ANKET® in #follicular #lymphoma (FL). 👏 https://lnkd.in/eUPv-Ejk

If you will be at ASH, we'd love to invite you to join us at our hosted luncheon on Sat Dec 7 - please feel free to register and share with others who may be interested as well. 

Join IFLI at the American Society of Hematology (ASH) Annual Meeting. We’re thrilled to be attending ASH2024! We look forward to collaborating with the leading minds in #hematology to support the latest in innovations and breakthroughs in the industry. The IFLI - Institute for Follicular Lymphoma Innovation team will be hosting a luncheon on Saturday, December 7, from 11:00 AM to 12:30 PM. 🥂 🍷 🍲 🍔 🎉 Please feel free to reach out if you would like an invitation to our reception. We look forward to connecting with you soon. Stay tuned for further updates during the conference.

Please check our last report in Science Immunology on IL-2v-armed tetraspecific NK cell engagers against B Cell lymphomas.

IFLI - Institute for Follicular Lymphoma Innovation is proud to announce a $2.1 million investment in a groundbreaking four-year research collaboration with Drs. Todd Fehniger and David Russler-Germain at Washington University in St. Louis. This funding supports the study titled “Using Circulating Tumor DNA #Sequencing to Advance Frontline Treatment of #Follicular #Lymphoma." Initially, IFLI provided a $1.3 million grant in 2022 to kickstart this important research. Now, with an additional $800,000, the study will expand to include 180 patients. These patients will undergo #PhasED-Seq #ctDNA-based measurable residual disease (#MRD) testing at pre-treatment, mid-treatment, and end-of-treatment stages. This approach aims to identify pre-treatment prognostic factors and assess the depth of response to therapy more accurately than traditional imaging methods. For more details on the Washington University study or IFLI, please visit IFLI’s website at https://www.i-fli.org/

Advancing Lymphoma Research.